Solitary Penile Metastasis of Prostate Cancer on 18F-Fluciclovine PET/CT Imaging in a Patient With PSA of 1 ng/mL

被引：7

作者：

Salavati, Ali ^{[1
]}

Schik, Allyssa N. ^{[1
]}

Koksel, Yasemin ^{[1
]}

Gencturk, Mehmet ^{[1
]}

Froelich, Jerry W. ^{[1
]}

机构：

[1] Univ Minnesota, Dept Radiol, Minneapolis, MN 55455 USA

来源：

CLINICAL NUCLEAR MEDICINE | 2020年 / 45卷 / 05期

关键词：

penile metastasis; prostate cancer; F-18-fluciclovine; prostatic-specific antigen; prostatic-specific antigen doubling time; definitive external beam radiation therapy; TUMORS;

D O I：

10.1097/RLU.0000000000002987

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

An 85-year-old asymptomatic man with suspected biochemical recurrence of prostate cancer underwent an F-18-fluciclovine PET/CT scan, which revealed a solitary suspicious tracer uptake in the dorsal right corporal body of the proximal pendulous penis. The patient underwent ultrasound-guided fine-needle aspiration of the penile lesion, which revealed metastatic prostate cancer. The patient had definitive external beam radiation therapy 3 years before the examination. At the time of scan, the prostatic-specific antigen (PSA) was only 1.0 ng/mL, although the PSA doubling time was 2.6 months. It is unusual to detect a solitary penile metastasis in a patient with a low level of PSA.

引用

页码：389 / 391

页数：3

共 50 条

[1] 18F-fluciclovine PET/CT detection of biochemical recurrent prostate cancer in patients with PSA levels <2.00 ng/mL
Garza, Daniel
Kandathil, Asha
Xi, Yin
Subramaniam, Rathan M.
[J]. NUCLEAR MEDICINE COMMUNICATIONS, 2021, 42 (08) : 907 - 913
[2] Cavernosal Metastasis From Prostate Cancer on 18F-Fluciclovine PET/CT
Nguyen, Ba D.
[J]. CLINICAL NUCLEAR MEDICINE, 2020, 45 (10) : E449 - E450
[3] Positive Findings on 18F-fluciclovine PET/CT in Patients with Suspected Recurrent Prostate Cancer and PSA levels ≤ 0.5 and ≤ 0.3 ng/ml
Lovec, P.
Savir-Baruch, B.
Gupta, G.
Wagner, R.
Gabriel, M. S.
Harkenrider, M. M.
Solanki, A. A.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S161 - S161
[4] UK guidelines on 18F-fluciclovine PET/CT in prostate cancer imaging
Afaq, Asim
Gleeson, Fergus
Scarsbrook, Andrew
Bradley, Kevin
Subesinghe, Manil
Macpherson, Ruth
Haroon, Athar
Patel, Neel
Chua, Sue
Wong, Wai-Lup
Vinjamuri, Sobhan
Warbey, Victoria S.
Cook, Gary J.
Bomanji, Jamshed
[J]. NUCLEAR MEDICINE COMMUNICATIONS, 2019, 40 (07) : 662 - 674
[5] 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment
England, Joseph R.
Paluch, Jeremy
Ballas, Leslie K.
Jadvar, Hossein
[J]. CLINICAL NUCLEAR MEDICINE, 2019, 44 (03) : e128 - e132
[6] Update on 18F-Fluciclovine PET for Prostate Cancer Imaging
Parent, Ephraim E.
Schuster, David M.
[J]. JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (05) : 733 - 739
[7] 18F-fluciclovine PET or PSMA PET for prostate cancer imaging?
Baris Turkbey
Peter L. Choyke
[J]. Nature Reviews Urology, 2020, 17 : 9 - 10
[8] PROSTATE CANCER 18F-fluciclovine PET or PSMA PET for prostate cancer imaging?
Turkbey, Baris
Choyke, Peter L.
[J]. NATURE REVIEWS UROLOGY, 2020, 17 (01) : 9 - 10
[9] PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer
Crocerossa, Fabio
Carbonara, Umberto
Parekh, Jayashree
Urdaneta, Alfredo
Weprin, Samuel
Damiano, Rocco
Grob, Mayer B.
Hampton, Lance J.
Paul, Asit
Autorino, Riccardo
Cantiello, Francesco
[J]. UROLOGIA INTERNATIONALIS, 2021, : 920 - 927
[10] Diagnostic performance of 18F-fluciclovine PET/CT in prostate cancer patients with rising PSA level ≤ 0.5 ng/ml after multiple treatment failures
Teyateeti, Ajalaya
Teyateeti, Achiraya
Ravizzini, Gregory C.
Xu, Guofan
Tang, Chad
Tu, Shi-ming
Macapinlac, Homer A.
Lu, Yang
[J]. AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 11 (02): : 87 - 98

← 1 2 3 4 5 →